已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation

噻替帕 医学 卡莫司汀 依托泊苷 养生 梅尔法兰 自体干细胞移植 内科学 肿瘤科 队列 移植 外科 造血干细胞移植 环磷酰胺 化疗
作者
Yarden Irit Cohen,Eyal Lebel,Eran Zimran,Adir Shaulov,Polina Stepensky,Sigal Grisariu,Batia Avni
标识
DOI:10.1016/j.jtct.2023.04.022
摘要

Autologous stem cell transplantation (ASCT) remains a cornerstone in the treatment of both Hodgkin lymphoma (HL) and various non-Hodgkin lymphoma (NHL) subtypes. BEAM (carmustine, etoposide, cytarabine, and melphalan) is the most frequently used conditioning regimen; however, owing due to limited availability and toxicity of carmustine, thiotepa-containing regimens have been suggested. We previously reported encouraging results in ASCT with a TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) conditioning regimen from 2000 to 2013. We aimed to update our experience with the TECAM regimen by adding our experience from 2013 to 2020 to the previously reported cohort. Moreover, we aimed to use the detailed data for the 2 transplant cohorts to identify improvements in ASCT outcomes in the recent era. We retrospectively analyzed all lymphoma patients who underwent ASCT at our center between January 2000 and December 2020. A total of 353 lymphoma patients were included (142 in the newer cohort added to 211 previously reported patients), all of whom were treated with our standard TECAM conditioning regimen. The cohort included 127 patients with HL, 107 with DLBCL, and 119 with other NHL subtypes. The newer cohort was characterized by significantly poorer Eastern Cooperative Oncology Group Performance Status (ECOG-PS) prior to ASCT (45.7% versus 19.3% with ECOG-PS ≥1; P < .01), whereas a higher proportion of patients entered transplantation in complete response (CR) (71.9% versus 47.8%; P < .01). The median follow-up after ASCT was 136.4 months (95% confidence interval [CI], 91.4 to 181.4 months). The 3-year progression-free survival (PFS) and overall survival (OS) rates post-ASCT for the entire cohort were 59.8% and 79.3%, respectively. Evaluating the 303 of 353 patients (86.4%) who entered ASCT with a responsive disease—a population that represents today's approach to the selection of patients for ASCT—the 3-year PFS and OS rates were 61.5% and 81.9%, respectively. In this population, the 3-year PFS rate was 62.2% for HL, 62.6% for DLBCL, 64.3% for primary central nervous system lymphoma (PCNSL), and the 3-year OS rate were 90.1%, 75.2%, and 78.6%, respectively. OS was significantly better in the newer cohort (P < .01), but not when evaluating only patients who entered ASCT with responsive disease. Dose reductions, poor disease status, and poor ECOG-PS at ASCT entry were associated with worse outcomes across all lymphoma subtypes. In accordance with our previous report, patients entering transplantation for DLBCL with a partial response achieved similar outcomes as those with a CR. Eighteen patients died within the first 100 days, 8 due to disease progression and 10 due to transplantation-related complications (2.8%). There were no cases of interstitial pneumonitis syndrome. Twenty-two cases (6.2%) of secondary malignancies were documented. Our results confirm that TECAM is an effective and safe conditioning regimen for ASCT in patients with HL and various NHLs, including favorable results in PCNSL. Despite a higher proportion of frail patients, the newer cohort's outcomes were favorable, driven by better lymphoma control pretransplantation. In the DLBCL cohort, ECOG-PS had more prognostic value than achieving a CR pre-ASCT, a finding relevant to the optimal allocation of patients to different treatment options in the era of chimeric antigen receptor T cell availability.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
醉倒天瓢完成签到 ,获得积分10
刚刚
谨慎哈密瓜完成签到,获得积分10
1秒前
所所应助姜姜不姜就采纳,获得10
3秒前
3秒前
desson发布了新的文献求助10
3秒前
wwdd发布了新的文献求助10
8秒前
10秒前
15秒前
木宁lj完成签到,获得积分10
16秒前
李昕123发布了新的文献求助10
16秒前
18秒前
朝气完成签到,获得积分10
19秒前
研友_VZG7GZ应助wwdd采纳,获得10
20秒前
哈哈哈完成签到 ,获得积分10
20秒前
WYJ完成签到,获得积分10
20秒前
菜狗发布了新的文献求助10
21秒前
星宫韩立完成签到 ,获得积分10
21秒前
22秒前
汉堡包应助科研通管家采纳,获得10
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
领导范儿应助科研通管家采纳,获得10
22秒前
22秒前
真的不会完成签到,获得积分10
23秒前
Tangerine完成签到 ,获得积分10
25秒前
老六完成签到 ,获得积分10
27秒前
27秒前
zwz完成签到,获得积分20
27秒前
jimmyhui完成签到,获得积分10
30秒前
星宫金魁完成签到 ,获得积分10
30秒前
悦耳的万言完成签到,获得积分10
32秒前
33秒前
小小鱼完成签到 ,获得积分10
33秒前
zwz发布了新的文献求助10
33秒前
科目三应助zzz采纳,获得10
34秒前
十四吉完成签到 ,获得积分10
35秒前
苹果丑应助kjding采纳,获得10
36秒前
36秒前
36秒前
无语的稀发布了新的文献求助10
37秒前
不安白易完成签到 ,获得积分10
38秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 890
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3256743
求助须知:如何正确求助?哪些是违规求助? 2898891
关于积分的说明 8302965
捐赠科研通 2568062
什么是DOI,文献DOI怎么找? 1394872
科研通“疑难数据库(出版商)”最低求助积分说明 652924
邀请新用户注册赠送积分活动 630631